ClinicalTrials.gg
CompletedNCT06402721Updated Mar 12, 2025

A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function

A Phase 1 interventional study of BAY3283142 in Chronic Kidney Disease and Hepatic Impairment, sponsored by Bayer. Completed at 1 site in United States. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by Bayer · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Enrollment
26th of 32
24 · median 98
Started
2024
with 6 others
Phase 1
12 of 49
none open now
Registered
38th of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 26th largest by enrollment of the 32 interventional ones that give a count, is one of 7 that started in 2024, is one of 12 in phase 1, and was the 38th registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years to 79 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

Researchers are looking for a better way to treat people who have chronic kidney disease (CKD).

CKD is a condition in which the kidneys' ability to work properly gradually decreases over time. The kidneys help the body get rid of waste through urine and filter the blood before sending it back to the heart. When kidney function decreases, waste builds up in the body, which can cause various complications.

The study treatment, BAY 3283142, is under development to treat CKD. It works by activating a protein called soluble guanylate cyclase (sGC) that generates cGMP - a molecule that relaxes blood vessels and is thought to have beneficial effects in CKD. BAY3283142 is broken down in the liver by a specific enzyme before it is removed from the body.

In this study, researchers want to understand how a mild or moderate reduction in liver function affects the blood levels of BAY3283142.

The main purpose of this study is to learn how BAY3283142 moves into, through, and out of the body, after a single dose of BAY3283142 in participants with reduced liver function.

For this, the researchers will analyze:

  • Area under the curve (AUC): a measure of the total amount of BAY3283142 in participants' blood over time
  • Maximum observed concentration (Cmax): the highest amount of BAY 3283142 in participants' blood The AUC and Cmax values for participants with reduced liver function will be compared with the values for participants with normal liver function.

The study participants will be assigned to one of the four treatment groups based on their liver function:

  • Group 1: participants with mild reduction in liver function
  • Group 2: participants with moderate reduction in liver function
  • Groups 3 and 4: participants with normal liver function who will be matched for age, weight, and gender with participants with reduced liver function All participants will take a single dose of BAY3283142 as a tablet by mouth without food.

Each participant will be in the study for around 5 to 6 weeks, which includes:

  • a visit within 28 days of starting treatment to confirm if the participant can take part in this study
  • a hospital stay for 7 days during which the participant will be given a single dose of BAY3283142 and the study doctor will monitor the participant's health
  • a visit after 7 to 10 days of taking BAY3283142 during which the study doctor will perform a health check-up on the participant

During the study, the doctors and their study team will:

  • check participants' health by performing tests such as blood and urine tests, blood pressure measurements, and checking heart health using an electrocardiogram (ECG)
  • ask the participants questions about how they are feeling and what adverse events they are having An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective of whether they think it is related or not to the study treatment.

Access to study treatment after the end of this study is not planned. Participants with liver problems can continue taking their other prescribed medicines as usual.

03

Conditions studied

  • Chronic Kidney Disease
  • Hepatic Impairment

Keywords

  • CKD
04

Who can participate

Ages eligible
18 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 79 years (both inclusive) at the screening visit
  • Participants with hepatic impairment classified as A or B

    • Disease confirmed by histopathology, (e.g. previous liver ), laparoscopy, CT, MRI, ultrasound or fibroscan
    • Stable liver disease in the last 2 months
  • Participants who have normal hepatic function and are overtly healthy.
  • (BMI): 18 to 36 kg/m*2 (both inclusive).
  • Male or female. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

    • Male participants: Must agree to use contraception/barrier as detailed below:

      • Agree to use a male condom and should also be advised of the benefit for a female partner to use a highly effective method of contraception as a condom may break or leak when having sexual intercourse with a woman of who is not currently pregnant.
      • Agree to use a male condom when engaging in any activity that allows for passage of ejaculate to another person.
    • Female participants: A female participant is eligible to participate if she is not pregnant or breast feeding, and one of the following conditions applies:

      • Is a woman of nonchildbearing potential (WONCBP)
      • Is a women of childbearing potential (WOCBP) and using a contraceptive method that is highly effective (with a failure rate \< 1% per year), with low user dependency, starting from signing the form and for at least 10 days after the intake of study intervention. The investigator should evaluate the potential for contraceptive method failure (e.g. noncompliance, recently initiated) in relationship to the dose of study intervention.
  • A WOCBP must have a negative highly sensitive pregnancy test within 24h before the first dose of study intervention.
  • Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

Exclusion criteria

Exclusion Criteria:

  • Severe ascites of more than 6 L (estimated by ultrasound)
  • Evidence of hepatic encephalopathy related to chronic liver disease > grade 2 (exclusion by Number Connection Test).
  • Renal failure with an estimated ≤40 mL/min (according to CKD-EPI equation).
  • Relevant diseases within the last 4 weeks prior to first study drug intervention.
  • Acute diarrhea or constipation within 14 days before the predicted first dosing day.
  • Febrile illness within 2 weeks prior to the admission of the study center
  • Tendency for vasovagal reactions (e.g. after venipuncture) or syncope.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Group 1: Mild hepatic impairment

    Participants with mild hepatic impairment.

    Drug: BAY3283142

  • Experimental
    Group 2: Moderate hepatic impairment

    Participants with moderate hepatic impairment.

    Drug: BAY3283142

  • Experimental
    Group 3 and 4: Normal hepatic function (control group)

    Control group(s) of age-, weight-, and gender-matched participants with normal hepatic function.

    Drug: BAY3283142

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the curve (AUC) of BAY3283142

    AUC(0-tlast) will be used as main parameter, if mean AUC cannot be reliably determined in all participants.

    Time frame: On Day 1 (dosing day), Day 2, Day 3, Day 4, Day 5, and Day 6.

  2. Maximum observed drug concentration (Cmax) of BAY3283142

    Time frame: On Day 1 (dosing day), Day 2, Day 3, Day 4, Day 5, and Day 6.

Secondary outcomes

  1. Number of participants with treatment-emergent adverse events

    Time frame: 7 days after last administration of study drug

07

Study locations

1 site
  • Orlando Clinical Research Center (OCRC)
    Orlando, Florida 32809-3017, United States
08

References and documents

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2024 to primary completion in Feb 2025, 9 months.

Of 77 industry-sponsored phase 1 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 9 months is above that.

Counting every sponsor, half of 109 studies reached it within 11 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2024
First posted
May 7, 2024
StartActual
May 17, 2024
Primary completionActual
Feb 24, 2025
CompletionActual
Feb 24, 2025
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06402721
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
May 7, 2024
Start date
May 17, 2024
Primary completion
Feb 24, 2025
Completion
Feb 24, 2025
Last update
Mar 12, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nurandociguat

Start the discussion